Vivani to Merge Cortigent with ClearOne in Nasdaq Deal
Vivani Medical plans to merge subsidiary Cortigent with Nasdaq-listed ClearOne, renaming the combined company Cortigent Holdings under ticker 'CRGT'.
Vivani Medical announced Monday it has entered a merger agreement to combine its wholly owned subsidiary Cortigent, Inc. with a subsidiary of Nasdaq-listed ClearOne, Inc. (CLRO), a move that would bring the Cortigent brand to public markets under a new identity.
Under the terms of the deal, ClearOne would shed its current name and ticker symbol, rebranding as Cortigent Holdings, Inc. — operating under the name Cortigent — and trading on Nasdaq under the proposed ticker "CRGT." The transaction represents a reverse-merger-style pathway, giving Cortigent access to an existing publicly listed shell while bypassing a traditional IPO process.
Read more Securitize Eyes SPAC IPO to Push Asset Tokenization Mainstream →
The strategic rationale is straightforward: Vivani gains a public market vehicle for Cortigent without the cost and timeline burden of a standalone listing, while ClearOne shareholders gain exposure to a new underlying business. Deals of this structure have grown in popularity as companies seek faster, lower-friction routes to public capital markets amid a sluggish IPO environment.
The renamed entity, Cortigent Holdings, would carry forward the Cortigent brand prominently, signaling that Vivani intends the merged company to be defined by its subsidiary's identity rather than ClearOne's legacy communications technology business. The outcome of the merger remains subject to shareholder approval and standard regulatory review.
Continue reading at GlobalNewswire.
